Intensity Therapeutics Reports $2.4 Million Net Loss in Q1 2026, Plans for Future Funding

Intensity Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $2.4 million, a decrease from the $3.3 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $2.5 million, down 25.6% from $3.4 million in the prior year. This reduction was primarily driven by a significant decrease in research and development expenses, which fell by 45% to $1.2 million, compared to $2.2 million in the previous year. The decrease in R&D spending was largely attributed to a pause in new site activations and patient enrollments in the INVINCIBLE-3 Study due to funding constraints.

As of March 31, 2026, Intensity Therapeutics reported total assets of $12.3 million, a decline from $14.1 million at the end of 2025. The company's cash and cash equivalents stood at $10.2 million, down from $11.9 million at the end of the previous fiscal year. Current liabilities increased slightly to $2.2 million from $2.1 million, while total stockholders' equity decreased to $10 million from $11.9 million, reflecting the ongoing operational losses and the impact of stock-based compensation.

In terms of strategic developments, the company has been actively managing its capital structure. In March 2026, Intensity Therapeutics adjusted its At The Market Offering Agreement to allow for the sale of up to $60 million in common stock. During the first quarter, the company raised approximately $0.2 million through the issuance of 16,154 shares under this agreement. Additionally, the company has plans to resume patient enrollment in the INVINCIBLE-3 Study by the third quarter of 2026, contingent upon securing sufficient funding.

Operationally, the company has made progress in its clinical programs, particularly with its lead product candidate, INT230-6. The company has successfully manufactured multiple large-scale batches of INT230-6 and has developed Phase 3 quality analytical methods for its components. However, the company has faced challenges, including a pause in patient enrollment for the INVINCIBLE-4 Study due to a need to revise the dosing regimen. Preliminary data from this study indicated a 71% pathological complete response rate in patients receiving INT230-6, compared to 33% in the standard of care group.

Looking ahead, Intensity Therapeutics anticipates continued significant expenses as it advances its clinical studies and seeks regulatory approvals for its product candidates. The company has expressed substantial doubt about its ability to continue as a going concern without additional capital, emphasizing the need for further funding to support its operations and growth strategy. The company plans to finance its operations through a combination of equity offerings and convertible debt, while also exploring potential collaborations and licensing arrangements.